[Experimental and clinical evaluation of latamoxef during the peripaturient period].
The concentrations of latamoxef (LMOX) in maternal serum, fetal cord serum and amniotic fluid were measured simultaneously at various times after administration to parturient women. The drug concentrations in fetal cord serum taken from 11 minutes to 12 hours and 37 minutes after administration ranged from 1.1 to 16 micrograms/ml. At the points from 3 to 5 hours after administration the maximum level of LMOX seems to be attained there. LMOX in amniotic fluid was increasing gradually to be attained 21.0 micrograms/ml as the peak concentration at 5 hours after administration. Thereafter, it began to decrease very slowly, 6.9 micrograms/ml was still kept in amniotic fluid at 19 hours after. These findings lead expectation that the effective concentration to mainly recognized pathogens from obstetrical and gynecological infections was kept in amniotic fluid through 19 hours or more. LMOX was given to each 4 peripartal and puerperal infections and 11 patients with premature rupture of the membranes for the purpose of prophylaxis. All cases showed effective responses clinically and bacteriologically. Neither noteworthy adverse reactions nor laboratory data abnormalities were caused throughout the studies.
D000328:Adult; D000653:Amniotic Fluid / Q000378:metabolism; D001424:Bacterial Infections / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008431:Maternal-Fetal Exchange; D008895:Milk, Human / Q000378:metabolism; D009070:Moxalactam / Q000378:metabolism* / Q000627:therapeutic use; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy*
D009070:Moxalactam